SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Snowflake, Inc. engages in the provision of cloud data warehousing software. The firm offers Data Cloud, an ecosystem where Snowflake customers, partners, data providers, and data consumers can break down data silos and derive value from data. Its platform supports a range of use cases including data warehousing, data lakes, data engineering, data science, data application development, and data sharing. The cloud-native architecture consists of layers across storage, compute, and cloud services. The storage layer ingests structured and semi-structured data to create a unified data record. The compute layer provides dedicated resources to enable users to access common data sets for many use cases without latency. The cloud services layer optimizes each use case's performance requirements with no administration. The company was founded by Marcin Zukowski, Thierry Cruanes, and Benoit Dageville on July 23, 2012 and is headquartered in Menlo Park, CA.

Snowflake Inc

Snowflake shares rallied significantly following strong quarterly financial results that beat expectations and included an upward revision to full-year product revenue guidance. While retail sentiment is overwhelmingly bullish, some traders are debating the stock's high valuation relative to its current profitability.

Credo Technology Group Holding Ltd. engages in the development of connectivity solutions and products for the data infrastructure market. Its products include integrated circuits, active electrical cables, and SerDes chiplets. The company was founded by Chi Fung Cheng and Yat Tung Lam on 2008 and is headquartered in George Town, Cayman Islands.

Credo Technology Group Holding Ltd

Credo Technology is experiencing significant downward pressure following its recent earnings report, despite beating estimates and raising guidance. Traders are debating whether the sell-off is an overreaction driven by concerns over margin compression, high customer concentration, and macro-economic factors, or if the stock is correcting from unsustainable valuation levels.

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and fibre channel storage area networking business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcom shares experienced significant volatility following a third-quarter earnings report that featured record revenue and a massive multi-year AI semiconductor growth outlook, though a softer-than-expected fourth-quarter forecast initially pressured the stock. The community remains deeply divided, with bulls highlighting the long-term AI guidance and custom chip partnerships while skeptics question the company's reliance on a limited number of customers and long-term infrastructure financing.

Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development, and commercialization of novel products for the treatment of genetic diseases. Its products include Crysvita, Mepsevii, Dojolvi, and Evkeeza. The company was founded by Emil D. Kakkis in April 2010 and is headquartered in Novato, CA.

Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc

Ultragenyx is trending following a significant share price decline after the Phase 3 Aspire study of its experimental Angelman syndrome drug, apazunersen, failed to meet both its primary and key secondary endpoints. While some traders are expressing concern over the clinical setback and the company's cash burn, others see a potential buying opportunity, pointing to the company's established commercial portfolio and upcoming catalysts for its remaining pipeline.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is trending as traders speculate on potential clinical data readouts and future catalysts, while monitoring price action near recent support levels ahead of upcoming scientific conferences. The community remains divided between those expecting a significant recovery driven by the company's siRNA pipeline and those expressing frustration over persistent downward price pressure and uncertainty regarding non-ambulatory patient treatment.

Magnite, Inc. provides a technology solution to automate the purchase and sale of digital advertising inventory for buyers and sellers. It features applications and services for digital advertising sellers including websites, mobile applications, and other digital media properties. The company was founded by Frank Addante, Duc Chau, Craig Roah, Julie Mattern and Brian D. Baumgart on April 20, 2007 and is headquartered in New York, NY.

Magnite Inc

Magnite is attracting investor attention as market sentiment shifts favorably regarding potential benefits from the ongoing Google AdTech antitrust case, with analysts suggesting that court-ordered behavioral remedies could favor independent supply-side platforms. Investors are also closely watching the company's growth in Connected TV (CTV) and its ability to capture ad spend as the advertising landscape evolves.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Investors are closely watching Oracle ahead of its upcoming earnings report on September 10, with sentiment divided between concerns over the company's aggressive debt-fueled AI infrastructure spending and bullish expectations for growth in its cloud infrastructure business. While some traders view recent dips as a buying opportunity given the firm's significant contracted backlog, others remain cautious due to ongoing analyst price target cuts and skepticism regarding its ability to quickly convert infrastructure investments into meaningful cash flow.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

Summit Therapeutics is trending following the announcement of a $500 million underwritten public stock offering, which has sparked significant debate among traders regarding dilution versus the company's need for capital to support the ongoing development and commercialization of ivonescimab. While some investors view the capital raise as a necessary step for the upcoming PDUFA catalyst, others have expressed frustration over the timing and the potential for increased downward pressure on the stock price.

Palo Alto Networks, Inc. engages in the provision of network security solutions to enterprises, service providers, and government entities. It operates through the following geographical segments: the United States, Israel, and Other Countries. The company was founded by Nir Zuk in March 2005 and is headquartered in Santa Clara, CA.

Palo Alto Networks Inc

Palo Alto Networks shares are under pressure as investors weigh strong quarterly earnings against concerns over the company's decelerating organic revenue growth and high valuation multiples. While some analysts maintain bullish price targets citing platformization and AI-driven cybersecurity demand, market sentiment remains cautious as the stock faces technical selling and broader sector weakness.

Algorand is a scalable, secure, and decentralized digital currency and smart contract platform. Its protocol uses a variation of Proof-of-Stake (PoS) called Pure PoS (PPoS) to secure the network and reach consensus on block production. Developers can build decentralized applications (dApps) using familiar programming languages, including Python, which Algorand supports natively. Its infrastructure enables various use cases, including payment systems, digital identity solutions, supply-chain tracking, and financial services. The protocol's architecture allows for tokenization of assets and the development of smart contracts, while its technical specifications support both retail users seeking basic transaction capabilities and enterprises requiring more, complex, blockchain solutions.

Algorand

Algorand is receiving attention from traders focused on its role in quantum-resistant blockchain technology and potential institutional adoption, with ongoing debates between bulls optimistic about price recovery and bears skeptical of long-term value. While some community members are accumulating the token based on these technical developments and future market cycles, others remain critical of the project's price performance and foundation activities.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Will Trump 2.0 Nurse Biotechs Back To Health: 10 Stocks Retail Is Watching

Equity

Less stringent requirements in pharmaceuticals and biotechnology could help by prompting accelerated drug approvals.


Sorrento Therapeutics, Inc. engages in the research, development, and manufacture of biopharmaceutical products. It operates through the Sorrento Therapeutics and Scilex segments. The Sorrento Therapeutics segment consists of developing a portfolio of next generation treatments for three major therapeutic areas: cancer, infectious disease, and pain. The Scilex segment is largely organized around the company's non-opioid pain management operations. The company was founded by Henry H. Ji in 1989 and is headquartered in San Diego, CA.

Feed

News

Sentiment

Fundamentals

Info